EXO

The Iris handheld ultrasound system now has clearance for AI lung and cardiac applications. [Image courtesy of Exo]Exo announced today that it launched its FDA-cleared cardiac and lung AI applications for the Iris handheld ultrasound device.

The company now has FDA clearance for five different applications on Iris — cardiac, lung, bladder, hip and thyroid. It expects to double that number by 2025.

Iris delivers high-performance medical imaging at a fraction of the size and cost of cart-based ultrasound. The system, built on Exo’s advanced silicon technology, fits in the pockets of caregivers. It enables immediate answers at the point of care for physicians, nurses, EMTs and clinicians in emergency, acute care, outpatient and home settings.

Exo unveiled the device for versatile imaging performance in point-of-care ultrasound (POCUS) in September 2023.

The company says the launch of its latest Iris functions simplify the process of obtaining and interp…

[Image courtesy of Exo]Exo today unveiled its Iris handheld ultrasound device for versatile imaging performance in point-of-care ultrasound (POCUS).

Santa Clara, California-based Exo said Iris delivers high-performance medical imaging at a fraction of the size and cost of cart-based ultrasound. The system, built on Exo’s advanced silicon technology, fits in the pockets of caregivers. It enables immediate answers at the point of care for physicians, nurses, EMTs and clinicians in emergency, acute care, outpatient and home settings.

Iris blends a simple user experience with powerful, real-time AI to provide instant answers at users’ fingertips. Exo’s patented SweepAI technology automatically acquires images with a sweep of the caregiver’s risk. The company says this reduces operator dependence and bias, ensuring consistent and accurate imaging.

Exo said it equipped Iris with its Bladder AI solution to help caregivers determine bladder …

Exo announced today that it relocated its headquarters in Santa Clara, California, doubling the size of its previous location.

The new facility at 4201 Burton Drive occupies 50,000 square feet. It features areas for manufacturing and R&D. Exo plans to continue hiring for roles in software, hardware, sales and customer success. The space also includes two state-of-the-art clinical rooms for developing and validating medical imaging advancements.

According to a news release, the headquarter relocation follows a year of rapid growth for Exo. The company increased its employee headcount by more than 20%. That overall headcount includes 150 employees based in the bay area. Exo expects its new headquarters to serve as a hub for employees across departments.

The company said its new location also resides centrally to more attractions and amenities. Those include public transportation, restaurants and shopping centers.

“We’ve had an exceptional year o…

[Image from Exo]Exo announced today that it will acquire artificial intelligence (AI) developer Medo to make ultrasound imaging faster and simpler.

Redwood City, California-based Exo intends to integrate Medo’s proprietary Sweep AI technology into its ultrasound platform to make the imaging modality more accessible to a wider range of caregivers.

No financial terms for the acquisition were disclosed.

According to a news release, Canada-based Medo’s ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, giving non-experts the ability to conduct high-quality exams quickly and accurately.

The company brings with it two FDA-cleared AI algorithms, as well as more in development, plus access to an extensive library of millions of ultrasound images and longitudinal health data to speed up point-of-care ultrasound adoption across the healt…